Silexion Therapeutics Corp Warrant (SLXNW)

About SLXNW

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

13

Fundamentals

1-day range

$0.006$0.0065

Market cap

$21.3K

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

—

Dividend yield

—

Beta

-1.01

Avg. volume

—

Silexion Therapeutics Corp Warrant Competitors

Chosen by industry and closest market cap.

• SLXNW

  Silexion Therapeutics Corp Warrant

  $0.0054

  ▼ 10.00%
  Market cap $21.3KP/E —
  $0.0051$0.1508
• BKHA

  Black Hawk Acquisition Corporation Class A Ordinary Shares

  $6.01

  ▼ 12.26%
  Market cap $—P/E 136.64
  $9.5$23
• TVGNW

  Tevogen Inc. Warrant

  $0.0689

  ▼ 1.57%
  Market cap $320.8KP/E —
  $0.0253$0.08
• BTTC

  Black Titan Corporation Ordinary Shares

  $0.368

  ▼ 6.84%
  Market cap $1.02MP/E —
  $0.3415$10.05
• SCNI

  Scinai Immunotherapeutics Ltd. American Depositary Shares

  $0.752

  ▼ 16.63%
  Market cap $1.30MP/E 0.16
  $0.75$15.65
• SLXN

  Silexion Therapeutics Corp Ordinary Shares

  $0.153

  ▼ 19.05%
  Market cap $1.90MP/E —
  $0.2362$42.6
• CLDI

  Calidi Biotherapeutics Inc. Common Stock

  $0.837

  ▼ 3.79%
  Market cap $4.38MP/E —
  $0.82$27.84

P/E shows — for peers not currently carrying a live signal of their own.